No Prescription |
 |
 | ||
|
Crestor Generic Rosuvastatin |
|
| ||
No Prescription » Prescription Drugs 5 » Crestor Generic Rosuvastatin Rosuvastatin is an enzyme blocker (HMG-CoA reductase inhibitor) also known as a "statin." It is used along with a proper diet to help lower fats (triglycerides) and cholesterol in the blood. This drug is usually prescribed after non-drug treatment options have not been fully successful at lowering cholesterol (e.g. diet change increase in exercise weight loss if overweight). Reducing cholesterol and triglycerides help prevent strokes and heart attacks. Buy Crestor Generic Rosuvastatin and other Prescription Drugs 5 products online at Medstore. Buy Online at Medstore - Click Here!
About Crestor Generic Rosuvastatin: Product Type: Prescription Drugs 5 Crestor ( Generic Rosuvastatin ) Crestor (Generic Rosuvastatin) Generic Rosuvastatin 10mg 28 Tablets 10mg 56 Tablets 10mg 112 Tablets 10mg 14 Tablets 20mg 14 Tablets 20mg 28 Tablets 20mg 56 Tablets 20mg 112 Tablets 40mg 14 Tablets 40mg 28 Tablets 40mg 56 Tablets 5mg 112 Tablets 5mg 28 Tablets 5mg 56 Tablets 5mg 14 Tablets 10mg 28 Tablets 20mg 28 Tablets Generic Rosuvastatin Crestor
View more Prescription Drugs 5 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
